Nasdaq Non-Compliance Notice Hits SBC Medical Group After Director Exit, Even as Shareholders Greenlight Sweeping Governance Reforms

summarizeSummary

SBC Medical Group received a Nasdaq non-compliance notice after losing an independent director, leaving its board and audit committee short of independence requirements. Shareholders approved major governance changes, including opting out of Delaware's anti-takeover law and eliminating plurality voting.

check_boxKey Events · Corporate Governance and Compliance · SBC

• Nasdaq Non-Compliance Notice

  On July 10, 2026, Nasdaq notified SBC that it no longer meets independent director and audit committee requirements following Mike Sayama's departure. The board now has 4 members, only 2 of whom are independent, and the audit committee has 2 independent directors—one short of the required 3. The cure period extends to the earlier of the next annual meeting or July 9, 2027.

• Governance Overhaul Approved

  Shareholders approved all five charter amendments: eliminating plurality voting for directors, removing the for-cause removal provision, opting out of DGCL Section 203 (anti-takeover), adding officer exculpation, and technical changes. The Restated Charter became effective July 9, 2026.

• Amended Bylaws Adopted

  The board adopted amended and restated bylaws on July 8, 2026, updating quorum requirements, advance notice provisions for stockholder proposals and director nominations, incorporating universal proxy rules, and adding a majority vote resignation policy for directors.

• Director Election Results

  All four director nominees were elected: Yoshiyuki Aikawa (90.4M for), Yuya Yoshida (90.4M), Ken Edahiro (90.4M), and Fumitoshi Fujiwara (89.9M). MaloneBailey, LLP was ratified as auditor with 93.9M votes for.

auto_awesomeAnalysis · SBC · Industrial Applications And Services

A Nasdaq non-compliance notice landed on SBC Medical Group after independent director Mike Sayama's departure left the board with only two independent members and the audit committee one short of the required three. The company has until its next annual meeting or July 9, 2027, to appoint a new independent director and cure the deficiency. At the same annual meeting, shareholders approved sweeping governance changes—eliminating plurality voting, removing for-cause director removal, opting out of Delaware's anti-takeover statute, and adding officer exculpation—and adopted amended bylaws that tighten advance notice and proxy rules. These changes, combined with the Nasdaq deficiency, mark a critical governance inflection point for a company already under pressure from a 47% Q1 net income drop, ineffective internal controls, and heavy insider selling.